Keith L. Ligon

50.9k total citations · 11 hit papers
248 papers, 21.3k citations indexed

About

Keith L. Ligon is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, Keith L. Ligon has authored 248 papers receiving a total of 21.3k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Genetics, 119 papers in Molecular Biology and 76 papers in Cancer Research. Recurrent topics in Keith L. Ligon's work include Glioma Diagnosis and Treatment (134 papers), Cancer Genomics and Diagnostics (36 papers) and Cancer, Hypoxia, and Metabolism (20 papers). Keith L. Ligon is often cited by papers focused on Glioma Diagnosis and Treatment (134 papers), Cancer Genomics and Diagnostics (36 papers) and Cancer, Hypoxia, and Metabolism (20 papers). Keith L. Ligon collaborates with scholars based in United States, France and Germany. Keith L. Ligon's co-authors include Ronald A. DePinho, David H. Rowitch, David N. Louis, Shakti Ramkissoon, Lynda Chin, Cameron Brennan, Sandro Santagata, Jayne M. Stommel, Robert Bachoo and Patrick Y. Wen and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Keith L. Ligon

237 papers receiving 21.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Malignant astrocytic glioma: genetics, biology, and paths to treatment

2007 1.8k citations Jayne M. Stommel, Alexander H. Stegh et al. profile →
p16INK4a induces an age-dependent decline in islet regenerative potential

2006 785 citations Janakiraman Krishnamurthy, Matthew R. Ramsey et al. profile →
Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies

2007 699 citations Jayne M. Stommel, Alec C. Kimmelman et al. Science profile →
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

2008 573 citations Haoqiang Ying, Alec C. Kimmelman et al. profile →
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

2012 566 citations Shakti Ramkissoon, Keith L. Ligon et al. profile →
Epidermal growth factor receptor and Ink4a/Arf

2002 501 citations Elizabeth A. Maher, Keith L. Ligon et al. profile →
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015 433 citations Patrick Y. Wen, Sam Haidar et al. Neuro-Oncology profile →
Emerging insights into the molecular and cellular basis of glioblastoma

2012 425 citations Cameron Brennan, Keith L. Ligon et al. profile →
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

2013 419 citations Sandro Santagata, Keith L. Ligon et al. profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Shakti Ramkissoon, Keith L. Ligon et al. Neuro-Oncology profile →
Glioblastoma targeted therapy: updated approaches from recent biological insights

2017 322 citations Ahmed Idbaïh, Marc Sanson et al. profile →

Peers

Countries citing papers authored by Keith L. Ligon

Since Specialization

Citations

This map shows the geographic impact of Keith L. Ligon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith L. Ligon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith L. Ligon more than expected).

Fields of papers citing papers by Keith L. Ligon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith L. Ligon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith L. Ligon. The network helps show where Keith L. Ligon may publish in the future.

Co-authorship network of co-authors of Keith L. Ligon

This figure shows the co-authorship network connecting the top 25 collaborators of Keith L. Ligon. A scholar is included among the top collaborators of Keith L. Ligon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith L. Ligon. Keith L. Ligon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integration of omics data in the diagnosis and therapy of glioblastoma 2025 ·Brain Pathology ·(unknown), Melanie Schoof, Keith L. Ligon, Ulrich Schüller	0
2	High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples 2025 ·Nature Biomedical Engineering ·(unknown), (unknown), (unknown), Smitha Yerrum, Ye Zhang, (unknown), (unknown), (unknown), Mark A. Murakami, Morvarid Mohseni, Kin-Hoe Chow, Teemu P. Miettinen, Keith L. Ligon, Scott R. Manalis	1
3	P11.84.A PHASE 1 TRIAL OF MARIZOMIB ALONE AND IN COMBINATION WITH PANOBINOSTAT IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) 2023 ·Neuro-Oncology ·(unknown), (unknown), Mark W. J. Strachan, (unknown), (unknown), Jayne Vogelzang, Keith L. Ligon, Sanda Alexandrescu, Patricia Baxter, Nicholas A. Vitanza, (unknown), (unknown), Ying Yuan, Wendy B. London, Michelle Monje	1
4	Systematic characterization of antibody–drug conjugate targets in central nervous system tumors 2023 ·Neuro-Oncology ·Shannon Coy, Jong Suk Lee, Sabrina Chan, Terri Woo, Jacquelyn Jones, Sanda Alexandrescu, Patrick Y. Wen, Peter K. Sorger, Keith L. Ligon, Sandro Santagata	17
5	Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas 2022 ·Neuro-Oncology Advances ·Christopher Rota, Alexander Brown, (unknown), (unknown), (unknown), Kristine Pelton, (unknown), Matthew Schniederjan, Robert C. Castellino, Sara J. Buhrlage, Douglas A. Lauffenburger, Keith L. Ligon, Linda G. Griffith, Rosalind A. Segal	3
6	PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors 2022 ·Modern Pathology ·Jared K. Woods, Hart G.W. Lidov, Keith L. Ligon, Sandro Santagata, Susan Chi, Kee Kiat Yeo, Sanda Alexandrescu	7
7	Effect of PIK3CA variants on glioma-related epilepsy and response to treatment 2021 ·Epilepsy Research ·Steven Tobochnik, (unknown), (unknown), Keith L. Ligon, Jong Woo Lee	10
8	Tie2–FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma 2019 ·Cancer Research ·Xiaolong Li, Emmanuel Martínez-Ledesma, Chen Zhang, Feng Gao, Siyuan Zheng, Jie Ding, Shaofang Wu, Nghi Nguyen, (unknown), Patrick Y. Wen, Keith L. Ligon, W.K. Alfred Yung, Dimpy Koul	20
9	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma 2019 ·Cancers ·Janis Noonan, Monika A. Jarzabek, (unknown), Brenton Cavanagh, (unknown), (unknown), Leonie S. Young, Keith L. Ligon, Hanne Jahns, Daniella Zheleva, Jochen H.M. Prehn, Markus Rehm, Annette T. Byrne, Brona M. Murphy	10
10	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort 2018 ·Cancer Immunology Research ·J. Bryan Iorgulescu, Maya Harary, Cheryl K. Zogg, Keith L. Ligon, David A. Reardon, F. Stephen Hodi, Ayal A. Aizer, Timothy R. Smith	56
11	Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas 2018 ·Cancer Research ·Sharmistha Pal, David Kozono, Xiaodong Yang, Wojciech Fendler, (unknown), Jing Ni, John A. Alberta, Jean J. Zhao, Kevin X. Liu, Jie Bian, Nathalène Truffaux, William A. Weiss, Adam Resnick, Pratiti Bandopadhayay, Keith L. Ligon, Steven G. DuBois, Sabine Mueller, Dipanjan Chowdhury, Daphne A. Haas‐Kogan	71
12	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas 2015 ·Clinical Cancer Research ·Maïté Verreault, Charlotte Schmitt, Lauriane Goldwirt, Kristine Pelton, Samer Haidar, (unknown), Jérémy Guehennec, David Knoff, Marianne Labussière, Yannick Marie, Azra H. Ligon, Karima Mokhtari, Khê Hoang‐Xuan, Marc Sanson, Brian M. Alexander, Patrick Y. Wen, Jean‐Yves Delattre, Keith L. Ligon, Ahmed Idbaïh	81
13	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model 2015 ·Cancer Immunology Research ·David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff, Gordon J. Freeman	302
14	EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing 2014 ·Cancer Discovery ·Joshua M. Francis, Cheng‐Zhong Zhang, Cécile L. Maire, Joonil Jung, Veronica E. Manzo, Viktor A. Adalsteinsson, Heather Homer, Sam Haidar, Brendan Blumenstiel, Chandra Sekhar Pedamallu, Azra H. Ligon, J. Christopher Love, Matthew Meyerson, Keith L. Ligon	211
15	Neuropathology 2014 ·Modern Pathology ·Jennifer Ziskin, Yael Wilnai, Greg Enns, (unknown), Malak Abedalthagafi, Shakti Ramkissoon, Keith L. Ligon, Azra H. Ligon, Rebecca D. Folkerth, Sandro Santagata, Christina Appin, Stewart G. Neill, Robert H. Press, Roshan S. Prabhu, Ian Crocker	2
16	Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry 2011 ·Cancer Research ·Lívia S. Eberlin, Isaiah Norton, Allison L. Dill, Alexandra J. Golby, Keith L. Ligon, Sandro Santagata, R. Graham Cooks, Nathalie Y.R. Agar	241
17	Human Glioma Growth Is Controlled by MicroRNA-10b 2011 ·Cancer Research ·Galina Gabriely, Ming Yi, Ravi S. Narayan, Johanna M. Niers, Thomas Würdinger, Jaime Imitola, Keith L. Ligon, Santosh Kesari, Christine Esau, Robert M. Stephens, Bakhos A. Tannous, Anna M. Krichevsky	245
18	Expression of p16Ink4a Compensates for p18Ink4c Loss in Cyclin-Dependent Kinase 4/6–Dependent Tumors and Tissues 2007 ·Cancer Research ·Matthew R. Ramsey, Janakiraman Krishnamurthy, Xin‐Hai Pei, Chad Torrice, Weili Lin, Daniel R. Carrasco, Keith L. Ligon, Yue Xiong, Norman E. Sharpless	53
19	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies breakdown → 2007 ·Science ·Jayne M. Stommel, Alec C. Kimmelman, Haoqiang Ying, Roustem Nabioullin, (unknown), Ruprecht Wiedemeyer, Alexander H. Stegh, James E. Bradner, Keith L. Ligon, Cameron Brennan, Lynda Chin, Ronald A. DePinho	699
20	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities 2006 ·Cancer Research ·Elizabeth A. Maher, Cameron Brennan, Patrick Y. Wen, Laura Durso, Keith L. Ligon, Aaron Richardson, Deepak Khatry, Bin Feng, Raktim Sinha, David N. Louis, John Quackenbush, Peter McL. Black, Lynda Chin, Ronald A. DePinho	140

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact